Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations, conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at over 200 locations in more than 20 states across the U.S.